INDIANAPOLIS and LAKE ZURICH, Ill., June 7, 2023 /PRNewswire/ -- SpectronRx, a leading radiopharmaceutical developer and manufacturer, and RLS (USA), Inc. (Radioisotope Life Sciences), the third-largest nuclear medicine pharmacy network in the US, today announced an agreement that will significantly enhance the supply and availability of diagnostic and therapeutic radiopharmaceuticals. With this collaboration, both companies hope to further bridge the gap between drug development, manufacturing, distribution and patient care by improving production and increasing the availability of life-saving medicines.
"Radiopharmaceuticals are essential to diagnosing and treating diseases ranging from cancer to neurodegenerative disorders," said SpectronRx CEO John Zehner. "However, patient access can be limited due to the complex nature of providing these materials. Our partnership with RLS – a one-stop-shop for seamless distribution which sets the standard in quality as the only nationwide radiopharmacy network to have received The Joint Commission Gold Seal of Approval – will allow us to increase the availability of radiopharmaceutical options for patients and healthcare providers nationwide."
As part of the agreement, SpectronRx will manufacture radiopharmaceutical products for RLS and other partners, and RLS will distribute them. SpectronRx will utilize RLS's extensive radiopharmacy network and abundant manufacturing space to develop the products in bulk, after which RLS will prepare the units into patient-, organ-, and time-specific individual doses and deliver them to care providers locally when needed. SpectronRx will also provide services related to the manufacture and distribution of the products, including quality control and testing and regulatory compliance services.

Ad Statistics
Times Displayed: 19090
Times Visited: 362 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
"This partnership with SpectronRx is a win for patient care," said RLS CEO Stephen Belcher. "Our collaboration will not only help RLS expand our extensive, accredited network of radiopharmacies into oncology, it will also improve access to novel, life-saving radioisotope-based medicines, which are vital in delivering precision medicine solutions for patients everywhere."
In addition to enhancing the supply of diagnostic and therapeutic radiopharmaceuticals, the partnership also offers opportunities for innovation through research and development projects, in which both companies will collaborate on new products and processes. This joint effort will help further advance treatments available for patients needing nuclear medicine services. And it will ensure that those treatments are available when patients need them.